Search results
Results from the WOW.Com Content Network
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...
In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer in 2010) for the treatment of FAP based on clinical trial data. Tafamidis (20 mg once daily) slowed the progression of FAP over a 36-month ...
On the other hand, Pfizer's Vyndaqel is the first drug used for treatment of FAP, one of two forms of ATTR. The product is approved only in Europe. Prior to Vyndaqel, liver transplantation was the ...
Thorazine (chlorpromazine) – a phenothiazine antipsychotic used to treat schizophrenia, bipolar mania, and behavioral disorders in children. Notably, the first antipsychotic Tofranil ( imipramine ) – a tricyclic antidepressant used to treat depression, anxiety, agitation, panic disorder and bedwetting
The Vyndaqel family of drugs recorded a remarkable 61% growth, aided by increased patient diagnoses and heightened demand. Meanwhile, Comirnaty revenue plummeted by 37%, reflecting COVID-19's ...
Amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. Trading not far from its lowest split-adjusted level in thirteen years, the stock is an ...
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.
Amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. Pfizer anticipates full-year 2025 revenues in the range of $61.0 to $64.0 billion. This ...